Index · Artikel · FDA approves Raptor's drug for nephropathic cystinosis

FDA approves Raptor's drug for nephropathic cystinosis

2013-04-30 2
   
Advertisement
résuméWASHINGTON The Food and Drug Administration has approved an experimental drug from Raptor Pharmaceutical Corp to treat a rare genetic disorder that can cause irreversible tissue damage, organ failure and premature death. Raptor's shares rose as much
Advertisement

FDA approves Raptor's drug for nephropathic cystinosis


WASHINGTON The Food and Drug Administration has approved an experimental drug from Raptor Pharmaceutical Corp to treat a rare genetic disorder that can cause irreversible tissue damage, organ failure and premature death.

Raptor's shares rose as much as 15.6 percent on Tuesday.

The drug, Procysbi, is designed to treat nephropathic cystinosis, the most common form of a disease known as cystinosis, in which toxic levels of cystine, a naturally occurring amino acid, build up in the body's cells and organs. The disease, which affects some 500 patients in the United States, is usually fatal by the age of 10.

Procysbi is a delayed-release formulation of cysteamine bitartrate, a drug sold under the brand name Cystagon by Mylan Inc. The drugs work by lowering cystine levels, potentially delaying kidney and other damage. Mylan's product is the current standard of care.

Raptor's drug is designed to be given once every 12 hours, instead of once every six hours for Cystagon.

The company's shares were up 7.3 percent to $7.03 in afternoon trading on Nasdaq. Earlier they rose as high as $7.67.

(Reporting by Toni Clarke in Washington; Editing by Richard Chang and Phil Berlowitz)

  • FDA approves Raptor's drug for nephropathic cystinosis

    FDA approves Raptor's drug for nephropathic cystinosis
    WASHINGTON The Food and Drug Administration has approved an experimental drug from Raptor Pharmaceutical Corp to treat a rare genetic disorder that can cause irreversible tissue damage, organ failure and premature death. Raptor's shares rose as much
    2013-04-30 FDARAPTOR
  • FDA approves Roche leukemia drug Gazyva

    FDA approves Roche leukemia drug Gazyva
    n">U.S. regulators said on Friday they approved a new treatment from Roche Holding AG for patients with chronic lymphocytic leukemia (CLL) who have not previously been treated for one of the most common forms of blood cancer. The U.S. Food and Dru
    2013-11-01 ROCHELEUKEMA
  • FDA approves GSK's drug Nucala for severe asthma

    FDA approves GSK's drug Nucala for severe asthma
    WASHINGTON GlaxoSmithKline Plc won U.S. regulatory approval for its drug Nucala to treat severe asthma, the Food and Drug Administration said on Wednesday. The drug, Nucala, known also as mepolizumab, was approved for use in combination with other th
  • U.S. FDA approves Eli Lilly drug for psoriasis

    U.S. FDA approves Eli Lilly drug for psoriasis
    n">U.S. health regulators said on Tuesday they have approved a drug from Eli Lilly and Co to treat adults with moderate to severe cases of the skin condition plaque psoriasis. The injectable biotech medicine known chemically as ixekizumab will be
  • FDA approves Pfizer leukemia drug

    FDA approves Pfizer leukemia drug
    WASHINGTON Health regulators on Tuesday approved a Pfizer Inc pill for a rare type of leukemia, another step in the company's effort to expand its oncology business. The medicine, called Bosulif, treats chronic myelogenous leukemia (CML), a blood and
    2012-09-04 PFIZERLEUKEMIA
  • U.S. FDA approves Bayer/Onyx drug for a type of thyroid cancer

    U.S. FDA approves Bayer/Onyx drug for a type of thyroid cancer
    n">The U.S. Food and Drug Administration said on Friday it has expanded the approved use of the cancer drug Nexavar to include late-stage differentiated thyroid cancer. Differentiated thyroid cancer is the most common type of thyroid cancer, the F
    2013-11-22 THYROIDBAYERONYX
  • FDA approves Novartis's drug for painful skin disease

    FDA approves Novartis's drug for painful skin disease
    n">The U.S. Food and Drug Administration approved Novartis AG's injectable drug, Cosentyx, to treat adults with a moderate to severe skin disease called plaque psoriasis. Cosentyx was approved on Wednesday with a medication guide warning about a g
    2015-01-21 FDANOVARTIS
  • FDA approves Glaxo cancer drug Votrient

    FDA approves Glaxo cancer drug Votrient
    WASHINGTON U.S. regulators gave the nod to GlaxoSmithKline Plc's Votrient for a type of sarcoma on Thursday, following a positive advisory panel vote last month. The U.S. Food and Drug Administration approved the pill for people with soft-tissue sarc
    2012-04-26 GLAXOSMITHKLINE
  • FDA approves Baxalta's drug for rare bleeding disorder

    FDA approves Baxalta's drug for rare bleeding disorder
    n">The U.S. Food and Drug Administration said on Friday it approved Baxalta Inc's drug for use in patients with a type of rare bleeding disorder. The drug, Adynovate, was approved to control and reduce the frequency of bleeding episodes in patient
    2015-11-13 FDABaxalta
  • FDA approves J&J drug for advanced multiple myeloma

    FDA approves J&J drug for advanced multiple myeloma
    n">U.S. regulators have approved an experimental treatment from Johnson & Johnson that may offer hope to multiple myeloma patients who have run out of other options against the blood cancer. The U.S. Food and Drug Administration on Monday said
  • Teva gets FDA approval for cancer drug

    Teva gets FDA approval for cancer drug
    n">Israel's Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine. The drug, sold under the brand name Bendeka, is approved for treating cancer patient
    2015-12-08 FDATEVA
  • U.S. FDA approves J&J hepatitis C pill

    U.S. FDA approves J&J hepatitis C pill
    n">U.S. regulators on Friday approved the use of Johnson & Johnson's Olysio, also known as simeprevir, as a treatment for chronic infection with the liver-destroying hepatitis C virus. Olysio, a protease inhibitor that blocks a specific protei
    2013-11-22 FDA
  • FDA approval of Roche melanoma drug may come early

    FDA approval of Roche melanoma drug may come early
    LOS ANGELES U.S. regulators are moving quickly with Roche's application for targeted melanoma drug vemurafenib, which could receive approval as early as this week, according to a source familiar with the situation. A pivotal trial found that advanced
    2011-08-09 MELANOMAROCHE
  • FDA approves Roche skin cancer drug Zelboraf

    FDA approves Roche skin cancer drug Zelboraf
    WASHINGTON U.S. drug regulators on Wednesday approved a targeted skin cancer drug from Roche Holding along with its diagnostic test, an advance in personalized health care. The Food and Drug Administration was two months ahead of schedule in approvin
    2011-08-17 ROCHEZELBORAF
  • FDA approves Roche skin cancer drug

    FDA approves Roche skin cancer drug
    n">U.S. health regulators on Monday approved Roche's pill to treat an advanced form of the most common form of skin cancer, known as basal cell carcinoma. The drug, Erivedge, which was co-developed by Curis Inc, was given a green light by the Food
    2012-01-30 ROCHEAPPROVAL
  • FDA approves Sanofi/Regeneron colon cancer drug

    FDA approves Sanofi/Regeneron colon cancer drug
    n">The U.S. Food and Drug Administration said on Friday that it had approved the Sanofi SA and Regeneron Pharmaceuticals Inc drug Zaltrap for patients with metastatic colorectal cancer whose tumors have failed to respond to earlier treatment with
  • U.S. FDA approves GlaxoSmithKline's HIV drug Tivicay

    U.S. FDA approves GlaxoSmithKline's HIV drug Tivicay
    WASHINGTON The U.S. Food and Drug Administration said on Monday it has approved GlaxoSmithKline Plc's drug Tivicay to treat the most common strain of HIV, the virus that causes AIDS. The once-daily drug, known generically as dolutegravir, belongs to
  • Actelion hits six-year high after favorable FDA approval for drug

    Actelion hits six-year high after favorable FDA approval for drug
    ZURICH Shares in Swiss group Actelion climbed more than five percent to their highest since late 2007 on Monday on optimism it has a viable product to secure sales and profit after U.S. approval for a new heart and lung drug with a favorable label. T
    2013-10-21 ACTELIONOPSUMIT
  • Expert panel recommends FDA approve Takeda bowel disease drug

    Expert panel recommends FDA approve Takeda bowel disease drug
    n">An advisory panel of medical experts on Monday voted to recommend that U.S. health regulators approve an experimental drug for ulcerative colitis and Crohn's disease developed by Takeda Pharmaceutical Co. There were specific safety and efficacy
    2013-12-09 FDADRUGTakeda
  • FDA approves another GSK, Theravance lung drug

    FDA approves another GSK, Theravance lung drug
    n">The U.S. Food and Drug Administration approved GlaxoSmithKline Plc's new lung drug for treatment of chronic obstructive pulmonary disease (COPD), commonly known as smoker's lung. However, the inhaled treatment, Anoro Ellipta, will carry a warni
    2013-12-18 FDAGSKLUNGDRUG

TOP

  • Day/
  • Week/
  • Original/
  • Recommand

Updated